| Name | Title | Contact Details |
|---|
Were all on our own journey and we want to be a part of yours. Lets blaze your trail together. NMLS #469510 & 456899. Federally Insured by NCUA. Equal Housing Opportunity.
At Divcon Controls, our mission is to provide our customers with cost effective solutions to meet their exact building automation needs. We strive to accomplish this through technology, innovation, and award winning personal service. Simply put, with Divcon Controls and Delta Controls, integration is simplified, customers are satisfied.
Give your team the freedom to meet, create and collaborate without distractions. Silen is an Estonian manufacturer of unique silent spaces that gives everyone the opportunity to focus in an open space. Our founders, who have over 20 years of experience in providing soundproofing solutions, have designed our office pods and phone booths to be the most adaptable and sustainable on the market. Their sound expertise has allowed Silen products to record industry-leading sound reduction levels. See why companies like Airbus, Ernst & Young, Dell and Volkswagen Group use Silen products to increase their productivity.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.